Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
Paola Queirolo, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pier Francesco Ferrucci(MultiMedica), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Virginia Ferraresi(Cancer Institute (WIA)), Ruggero Ridolfi, Jacopo Pigozzo(Istituto Oncologico Veneto), Alessandro Scoppola(Istituto Dermopatico dell'Immacolata), Michele Guida(Istituto Tumori Bari), Francesco Spagnolo(Martin University), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Maresa Altomonte(University of Siena), Riccardo Marconcini(Azienda Ospedaliera Universitaria Pisana), Ester Simeone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimo Aglietta(Candiolo Cancer Institute), Maria Grazia Bernengo(University of Turin), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Gaetana Rinaldi(AOL (United States)), Mario Mandalà(University of Perugia)
Cited by 11
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k